Technological innovations in medicine can help treat illness and improve health, but they also drive healthcare spending higher.
Technological innovations in medicine can help treat illness and improve health, but they also drive healthcare spending higher. In fact, medical technologies outweigh other factors that contribute to spending, including an aging population, increased public demand, and reduced efficiency.
Former Commonwealth Fund Harkness Fellow Bjorn Hofmann argues for more thoughtful and responsible implementation of health technology. Because technological advances can result in increased diagnostic accuracy, more conditions are detected and treated. This in turn leads to a perception of success, which then stimulates additional innovation.
Read more at The Commonwealth Fund: http://bit.ly/1HY2H9j
Health Equity Adjustments in Medicare HVBP Program Will Benefit Safety Net Hospitals, Study Says
March 29th 2024Medicare’s upcoming health equity adjustment in the Hospital Value-Based Purchasing (HVBP) program will reduce disproportionate penalization among safety net hospitals and those serving high proportions of Black patients, according to a recent study.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Ravulizumab-cwvz for Rare Autoimmune Disease
March 28th 2024Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.
Read More